Marco Maria Germani, Roberto Moretto, Tadayoshi Hashimoto, Volker Heinemann, Filippo Pietrantonio, Yoshiaki Nakamura, Sebastian Stintzing, Francesca Bergamo, Kei Muro, Alan P. Venook, Lena Weiss, Giulia Martini, Francesca Battaglin, Jumpei Soeda, Eva Blondeaux, Davide Ciardiello, Heinz-Josef Lenz, Takayuki Yoshino, Dominik Paul Modest, Chiara Cremolini. "Negative hyperselection as a predictive biomarker of benefit from first-line doublets + anti-EGFRs/bevacizumab (bev) in microsatellite stable (pMMR/MSS)
                    <i>RAS</i>
                    and
                    <i>BRAF</i>
                    wild-type (wt) and HER2− metastatic colorectal cancer (mCRC): An individual patient data pooled analysis of seven clinical trials (CTs).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.3550